Opens in a new tab

Rectal Cancer Rewrites the Surgery Pathway

FDA has granted accelerated approval to dostarlimab for MSI-H/dMMR stage II–III locally advanced rectal cancer. For selected responding patients, the treatment strategy can now be built around preserving the rectum rather than automatically progressing toward chemotherapy, radiation and major pelvic surgery.

November 18, 2026
Editorial
For selected MSI-H/dMMR rectal cancers, immunotherapy-led organ preservation is moving from experimental strategy toward regulated care.[Parilov] / Shutterstock.com

IPM Take

Avoiding rectal surgery is not simply “less treatment.” It can mean preserving bowel, urinary and sexual function and avoiding a permanent stoma. The price of organ preservation, however, is disciplined surveillance. A watch-and-wait pathway is only as safe as the MRI, endoscopy, imaging and follow-up system built around it.

Executive Summary

FDA granted accelerated approval to dostarlimab for previously untreated MSI-H/dMMR stage II or III locally advanced rectal cancer. The global AZUR-1 trial enrolled 154 patients. Independent central review had confirmed a sustained clinical complete response at 12 months in 47% of 116 evaluable patients, while investigator assessment reported 68% cCR12 among 144 evaluable patients. An exploratory analysis presented subsequently found 76% had a complete response when clinical and pathologically confirmed complete responses were considered together. No disease recurrence had been reported among responders after median follow-up exceeding two years at the time of the updated analysis.

Why it matters

  • Patients / advocates: Organ preservation can avoid major long-term functional consequences of rectal cancer treatment.
  • Diagnostics / pathology: MSI/MMR status now has immediate implications for the initial treatment pathway.
  • Clinicians: Complete response must be established and monitored through structured multimodal surveillance.
  • Hospitals / providers: Non-operative management requires more organised follow-up, not less care.

The FDA accelerated approval of dostarlimab in locally advanced rectal cancer changes the objective of treatment for a defined molecular subgroup. Instead of assuming that stage II or III rectal cancer must progress through chemotherapy, pelvic radiation and surgery, the new pathway allows patients with MSI-H/dMMR disease who achieve a sustained clinical complete response to enter non-operative management. The clinical value is unusually tangible: preserving the rectum may avoid permanent changes in bowel function, urinary complications, sexual dysfunction, infertility and, for some patients, a permanent colostomy.

The numbers need to be communicated carefully because different AZUR-1 analyses answer slightly different questions. FDA’s current efficacy assessment is based on independent central review, where 47% of evaluable patients had already achieved a sustained complete clinical response at 12 months, with additional responding patients still maturing toward that time point. The later updated AZUR-1 analysis released at ESMO reported a 76% overall complete-response rate when investigator-assessed sustained responses and patients with pathologically confirmed complete response after surgery were considered. Those figures are complementary, not interchangeable.

The policy implication is that biomarker testing and surveillance become part of the same organ-preservation strategy. MSI/MMR testing has to happen before the conventional pathway becomes irreversible, and patients managed without surgery must remain inside a demanding schedule of endoscopy, rectal MRI and systemic imaging. The FDA’s own postmarketing requirements call for longer follow-up on organ preservation, relapse and survival. The innovation here is therefore not simply immunotherapy replacing surgery; it is a molecularly selected care pathway that uses immunotherapy, diagnostics and surveillance to decide when surgery can safely be withheld.

Source & Evidence